Related Experiment Video
Updated: Aug 15, 2026

A Small-Scale Setup for Algal Toxicity Testing of Nanomaterials and Other Difficult Substances
Published on: October 10, 2020
Implications of council regulation 793/93 on the evaluation and control of existing substances
1Commission of the European Union, Brussels, Belgium.
Abstract:
The European Union (EU) programme on existing substances makes provision for the delivery by industry of data on substances produced or imported above certain quantities which will be used by the Commission to facilitate selection of priority lists of substances for which risk assessments will be carried out. The substances comprise three subsets of the existing substances listed in the European Inventory of Existing Commercial Chemical Substances (EINECS) according to the respective deadlines for delivery of the data. The risk assessments are performed by the member states according to a commission regulation 1488/94 supported by guidance documents, may require further data delivery or performance of tests by industry and must conclude that the substance is either of no concern, of concern and risk reduction measures are appropriate, or require further data or testing to arrive at one of the other conclusions. The EU programme on existing chemicals is coordinated with the related OECD programme which will allow chemicals evaluated under regulation 793/93 to constitute an EU contribution to OECD and to largely allow the community to avoid investing unnecessary resources in substances being evaluated by non-EC countries.
Related Concept Videos
Drug Regulation
Drug Classes and Categories
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Drug Control Governance: Regulatory Bodies and Their Impact
FDA Approved Drugs: Changes to Approved Drugs
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

